Cancer Reports (May 2022)

Clinical characteristics and outcomes of infants compared with children diagnosed with rhabdomyosarcoma: Analysis of surveillance, epidemiology and end results data from 2000 to 2016

  • Hannah D. Rees,
  • Nancy K. Hills,
  • Amit J. Sabnis,
  • Asmin B. Tulpule,
  • Tom K. Shimotake,
  • Robert E. Goldsby

DOI
https://doi.org/10.1002/cnr2.1503
Journal volume & issue
Vol. 5, no. 5
pp. n/a – n/a

Abstract

Read online

Abstract Background Rhabdomyosarcoma (RMS) is the most common soft‐tissue sarcoma of childhood, but occurs infrequently in infants (<1 year). Historically, infants with RMS have worse overall survival compared to other pediatric age groups. Aim This study aims to assess the clinical features and treatment factors associated with survival comparing infants to children aged 1–9 years diagnosed with RMS. Methods Children aged <10 years diagnosed with RMS between 2000 and 2016 were identified using the SEER database. Descriptive statistics were used to assess demographic, clinical, and treatment characteristics of infants and children with RMS. Kaplan–Meier estimates and Cox proportional hazards regression were performed to assess for factors associated with survival. Results Age <1 year was independently associated with an increased risk of mortality. Compared to children aged 1–9 years, fewer infants received standard of care therapy, that is, chemotherapy combined with local control (surgery and/or radiation; 86.8 vs. 75.7%; p = .009). In comparing the frequency of specific treatment modalities (used alone or in combination with other modalities), infants were less likely to receive radiation therapy (34.0 vs. 66.4%; p < .001) and more likely to receive surgery (68.9 vs. 57.5%; p = .02) than children aged 1–9 years. Across age groups, chemotherapy combined with local control was significantly associated with reduced mortality. Alveolar histology, metastatic disease, and Hispanic ethnicity were negatively associated with survival. Conclusions Age of <1 year was an independent risk factor for increased mortality from RMS compared to ages 1–9 years. Fewer infants were treated with chemotherapy combined with local control, the therapy associated with best survival in all age groups. Other factors contributing to differences in survival should be further explored.

Keywords